<DOC>
	<DOCNO>NCT02069678</DOCNO>
	<brief_summary>This multi-center study Hong Kong . This retrospective-prospective study HBeAg-negative chronic hepatitis B patient . HBeAg-negative patient entecavir follow liver clinic identify exist database . All patient HBV DNA test every 6 month clinic routine . Serum HBsAg level test residual serum sample pre-treatment last follow-up visit . Eligible patient discuss plan stop entecavir therapy . All patient write informed consent recruit study . All patient follow 12 month stop entecavir treatment . As entecavir commonly use antiviral drug Hong Kong Western country , investigator aim investigate validate use serum HBsAg quantification guide time stop entecavir HBeAg-negative patient . The result study provide scientific evidence use new serum marker predict sustain remission stop entecavir . In long-run , improve patient compliance , reduce need long-term antiviral reduce drug cost management HBeAg-negative chronic hepatitis B . All patient stop entecavir accord Asian Pacific guideline write informed consent close subsequent monitoring . In protocol , safety net re-treatment . There invasive procedure . There major ethical issue .</brief_summary>
	<brief_title>Serum Hepatitis B Surface Antigen Levels Guide Stopping Entecavir HBeAg-negative Chronic Hepatitis B</brief_title>
	<detailed_description>Chronic hepatitis B commonest cause liver cirrhosis hepatocellular carcinoma Hong Kong . Approximately 50 % patient negative hepatitis B e antigen ( HBeAg ) , indicate escape host immune clearance host . Oral antiviral drug effective suppress viral replication induce biochemical remission [ 1 ] . However , time stop oral antiviral agent controversial . Hepatitis B surface antigen ( HBsAg ) seroclearance recommend best time drug cessation HBeAg-negative patient [ 2,3 ] , occurrence uncommon especially among Asian patient . The Asian Pacific guideline recommend stop treatment serum HBV DNA become undetectable three time within 12 month [ 4 ] , approximately 50 % patient experience virologic relapse post-treatment [ 5,6 ] . HBsAg quantification show correlate concentration covalently close circular DNA liver [ 7 ] . In Hong Kong study among 53 HBeAg-negative patient stop lamivudine , HBsAg â‰¤ 100 IU/ml and/or reduction &gt; 1 log end treatment could predict sustain response 5 year post-treatment [ 8 ] . In word , probable patient low serum HBsAg level , may reflect low concentration virus inside liver , low risk viral relapse stop antiviral therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>1 . HBeAgnegative patient entecavir monotherapy least 24 month 2 . Undetectable HBV DNA PCRbased assay 3 separate occasion 6 month apart ( per Asian Pacific guideline 2008 ) . 3 . Normal ALT level accord local laboratory reference value 2 separate occasion 6 month apart 1 . Patients previously currently interferon therapy 2 . Patients experience another antiviral agent besides entecavir 3 . Patients hepatitis C virus infection indicate positive antiHCV serology test 4 . Patients Child 's B liver cirrhosis , cirrhotic complication hepatocellular carcinoma 5 . Patients organ transplantation 6 . Serious medical illness malignancy 7 . Age &lt; 18 year &gt; 65 year 8 . No patient consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>